KalVista Pharmaceuticals, Inc.

KALV

US4834971032

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
11.82 ^USD	-2.07%		+1.20%	-3.51%

06/06	KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	CI
03/06	Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	CI

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

November 02, 2023 at 04:00 pm IST

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13.

Latest news about KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06/06	CI
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	03/06	CI
Sector Update: Health Care Stocks Higher Late Afternoon	01/06	MT
Sector Update: Health Care	01/06	MT
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	31/05	MT
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	31/05	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	22/05	MT
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22/04	CI
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04	CI
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	12/03	CI
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03	CI
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	08/03	MT
KalVista Pharmaceuticals, Inc. Announces Board Changes	07/03	CI
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	07/03	CI
KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency	20/02	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing	17/02	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing	17/02	MT
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing	17/02	MT
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	16/02	CI
HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating	14/02	MT
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise	13/02	MT

Chart KalVista Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Sector

Pharmaceuticals

Calendar

04/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.07 USD

Average target price

29.8 USD

Spread / Average Target

+146.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KALVISTA PHARMACEUTICALS, INC.	-3.51%	509M
CSL LIMITED	+0.75%	92.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.16%	37.9B
BIOGEN INC.	-12.49%	33.73B
UCB	+73.89%	27.98B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	15.86B
INCYTE CORPORATION	-0.16%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.18%	11.67B
ALTEOGEN INC.	+171.57%	10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.45%	10.04B

Biopharmaceuticals

KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Pharmaceuticals

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Latest news about KalVista Pharmaceuticals, Inc.

Chart KalVista Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals